EpiCast Report: Nonalcoholic Steatohepatitis - Epidemiology Forecast to 2022

News provided by

Aug 22, 2013, 12:15 ET

NEW YORK, Aug. 22, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

EpiCast Report: Nonalcoholic Steatohepatitis - Epidemiology Forecast to 2022
http://www.reportlinker.com/p01600265/EpiCast-Report-Nonalcoholic-Steatohepatitis---Epidemiology-Forecast-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_Medicine

EpiCast Report: Nonalcoholic Steatohepatitis - Epidemiology Forecast to 2022

Summary

Nonalcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of a fatty, inflamed, and damaged liver. It resembles alcoholic liver disease, but occurs in people who drink little or no alcohol. NASH is becoming increasingly common with the alarming epidemic of obesity. As obesity is a major risk factor for other metabolic syndrome diseases, such as type 2 diabetes and dyslipidemia, the incorporation of weights from the age- and sex-specific prevalence of obesity in each of the 6MM adds granularity to the forecast analysis, which allowed GlobalData epidemiologists to provide a comprehensive forecast of the prevalent cases of NASH in the 6MM.

GlobalData's epidemiological analysis forecasts that prevalent cases of NASH in the 6MM (US, France, Germany, Italy, Spain, and UK) will grow by 8.24% over the next decade, from 29.38 million prevalent cases in 2012 to 31.80 million prevalent cases in 2022. The US and Germany will continue to have the highest number of prevalent cases in the 6MM during 2012–2022. The US will have 48.29% (15.36 million cases) of all prevalent cases in the 6MM in 2022, with the second largest annual growth rate (AGR) of 1.03% throughout the forecast period. Changes in the definition of nonalcoholic, which is the basis for defining NASH cases, the development of less invasive gold-standard diagnostic methods for NASH, and changes in the prevalence of the metabolic syndrome will influence the prevalence of NAFLD and NASH during the forecast period.

Scope

- The Nonalcoholic Steatohepatitis (NASH) EpiCast Report provides an overview of the risk factors and global trends of NASH in the 6MM (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiology forecast of NASH prevalent cases segmented by age (in five-year increments beginning at age 20 and ending at age =85 years) and sex in the 6MM.
- The NASH epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global NASH market.
- Quantify patient populations in the global NASH market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for NASH therapeutics in each of the markets covered.

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Upcoming Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 10
3.2.1 Increased age is associated with a worsened disease progression, prognosis, and mortality 10
3.2.2 Being a male is an independent risk factor in morbidly obese NASH cases 11
3.2.3 Metabolic conditions, such as type 2 diabetes, considerably increase the risk of NASH 13
3.3 Global Trends 14
3.3.1 US 15
3.3.2 5EU 16
3.4 Forecast Methodology 17
3.4.1 Sources Used 19
3.4.2 Forecast Assumptions and Methods 20
3.4.3 Sources Not Used 23
3.5 Epidemiology Forecast of Nonalcoholic Steatohepatitis (2012–2022) 24
3.5.1 Total Prevalent Cases of Nonalcoholic Steatohepatitis 24
3.5.2 Age-Specific Prevalent Cases of Nonalcoholic Steatohepatitis 26
3.5.3 Sex-Specific Prevalent Cases of Nonalcoholic Steatohepatitis 28
3.5.4 Age-Standardized Prevalence of Nonalcoholic Steatohepatitis 29
3.6 Discussion 30
3.6.1 Conclusions on Epidemiological Trends 30
3.6.2 Limitations of the Analysis 31
3.6.3 Strengths of the Analysis 32
4 Appendix 33
4.1 Bibliography 33
4.2 About the Authors 38
4.2.1 Epidemiologists 38
4.2.2 Reviewers 38
4.2.3 Global Director of Epidemiology and Health Policy 39
4.2.4 Global Head of Healthcare 40
4.3 About GlobalData 40
4.4 About EpiCast 41
4.5 Disclaimer 41

List of Tables

Table 1: Risk Factors and Comorbidities for NASH 10
Table 2: Reported Prevalence of NASH in the US and 5EU 14
Table 3: Reported Prevalence of NAFLD in the US and 5EU 15
Table 4: 6MM, Sources of Prevalence Data Used in the NASH Epidemiological Forecast 18
Table 5: 6MM, Prevalent Cases of NASH, Ages ?20 Years, Men and Women, N, Selected Years, 2012–2022 25
Table 6: 6MM, Prevalent Cases of NASH, By Age*, Men and Women, N (Row %), 2012 27
Table 7: 6MM, Prevalent Cases of NASH, Ages ?20 Years, By Sex, N (Row %), 2012 28

List of Figures

Figure 1: 5EU, Prevalence of NAFLD and Obesity, Ages ?20 Years, Men and Women, % 17
Figure 2: 6MM, Prevalent Cases of NASH, Ages ?20 Years, Men and Women, N, Selected Years, 2012–2022 25
Figure 3: 6MM, Prevalent Cases of NASH, By Age*, Men and Women, N, 2012 27
Figure 4: 6MM, Prevalent Cases of NASH, Ages ?20 Years, By Sex, N, 2012 29